Following these case reports, recently Brown et al. reported the results of the completed NCT02208362 phase I trial assessing the safety and efficacy of CAR-T therapy targeting IL-13Rα2 in 65 patients with recurrent high-grade glioma, primarily recurrent GBM (rGBM) [22]. Here, IL13RA2 is linked to central nervous system cancer.